Archives — May 2016 back to current month (29)
Four Active Mining Companies You Should Be Watching (05/31/2016)
The mining industry has been very busy over the last few months with the gold price showing signs of stabilizing, financings getting completed, preliminary economic assessments being released, prefeasibility studies being updated and M&A activity increasing. The market has a buzz once again and Thibaut Lepouttre of Caesars Report profiles several companies that are reaping the rewards of being very active right now.
Precious metals expert Michael Ballanger discusses the importance of caution and timing in gold investment.
What Recent Moves in the US Dollar Mean for Gold (05/28/2016)
Technical analyst Jack Chan offers an interpretation of the correction in progress in the gold sector.
The price of a barrel of oil has almost doubled from its low of $28 at the start of the year, prompting speculation that a recovery is underway, which may result in the revival of companies in the exploration, production and services sectors that have foundered since prices collapsed in 2015.
Precious metals expert Michael Ballanger discusses how investors should interpret the recent shifts in gold and silver "market tectonics."
Marc Faber, editor of the Gloom, Boom & Doom Report, is bullish on gold and oil and gas stocks.
Marc Davis of BNWNews profiles Amarillo Gold, a company that is finally poised to capitalize on a resurgent gold market.
Technical analyst Jack Chan finds gold stocks are on a short-term sell signal and reveals an excellent entry point.
Investment adviser Adrian Day discusses the merger announced today between Ares Capital and American Capital.
Streaming/royalty stocks have been darlings of the commodity investment world. In the precious metals sector, this type of company provides financing for mining companies in the form of an upfront cash payment in exchange for a percentage of production or revenues from the mine. Jason Hamlin of Gold Stock Bull profiles two streamers often overlooked by investors.
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.
Two Companies Poised to Catch Up to Gold Peer Group (05/17/2016)
After a mad dash to the upside for gold and a similar dash to the downside for the U.S. dollar, investors are getting their bearings once again. April's disappointing jobs report refocused everyone on the potential economic slowdown and a still-dovish Fed. Brien Lundin of Gold Newsletter paints the big picture of how speculation over the Fed's actions to raise interest rates is affecting gold and gold equities, and he discusses two companies that have not appreciated as much as their peers but are likely to soon catch up.
Goldcorp Went Ahead and 'Made My Day' (05/16/2016)
Michael Ballanger expounds on the Goldcorp/Kaminak deal and what it means for the gold market, and he dissects the most recent COT report.
Technical analyst Jack Chan reports the energy sector cycle is down and a multiweek correction is in progress, and discusses what that means.
Technical analyst Jack Chan reports that although gold speculation is at an all-time high, the gold price has not followed suit.
Double-Digit Yields from Around the World (05/13/2016)
In this bulletin, Adrian Day reviews three companies with strong yields. All three are under some pressure, but equally all are solid companies with very attractive yields.
Goldcorp is fresh off an announced transaction of $520M for Kaminak Gold, which is a big win for the industry. The company has been quietly putting dollars in juniors, like $16M in Gold Standard Ventures, and there could be more to come. In this article, Resource Maven Gwen Preston discusses possible target West Red Lake Gold Mines and how this company is shaping up to take advantage of the initial turnaround in the market.
The energy sector is a tricky place to invest right now, with a fine line separating the next bankruptcy candidate from a tenbagger. Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? helps investors navigate this minefield with three companies he believes will come out on top.
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully.
Legendary investor Stan Druckenmiller, founder of Duquesne Capital Management LLC, told the Sohn Investment Conference in New York last week that he is bullish on gold and bearish on the stock market. Gold, he told the conference, "is our largest currency allocation."
Joe Reagor of ROTH Capital Partners explains the factors that have kept uranium spot prices down, how much longer they will be in effect, and why uranium should be on investors' radar screens today. He also discusses four uranium companies that are in position to benefit from the looming uranium shortage.
After COT Data Shocker, No Surprise Gold Is Down (05/09/2016)
Technical analyst Jack Chan shows why Friday's COT data was so shocking and what it means for gold.
Energy Sector Showing Sell Signals (05/09/2016)
Technical analyst Jack Chan highlights sell signals in the energy sector.
Commercial Gold 'Hedgers' Turn Up the Heat (05/07/2016)
Michael Ballanger discusses the most recent COT report, which shows levels not seen since 2010–2011.
The two times mining companies add the most value are upon first discovery and when they are nearing development and production. Joe Reagor of ROTH Capital Partners focuses on the latter group, and in this interview with The Gold Report, he discusses a handful of gold and silver companies poised to move up the value curve even if gold and silver don't go up.
Give me Facts or at Least Logical Opinions (05/05/2016)
Bob Moriarty of 321Gold busts the myth of a Comex bank and examines the role of small speculators in commodities markets.
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential.
A battle royale is brewing between gold bulls and commercial traders who are short gold, says Brien Lundin, publisher of Gold Newsletter. That tug of war, which should play out in the coming weeks, could result in either a severe correction or a spectacular rise in the price of gold and silver. No matter which way it goes, in this interview with The Gold Report, Lundin recommends that investors continue to look at companies with world-class resources that are still being priced at a fraction of what their values should be. Lundin should know; some of his recommendations are up more than 400% from December and January.
If A=B and B=C, Does A=C? (05/03/2016)
No need to listen to the "experts" to understand the ins and outs of commodities markets, according to Bob Moriarty of 321Gold. If investors use common sense and basic tools available online, they too can be successful.
|"For 2016, GPR reported revenue of $61.8M; we reiterate our Buy."|
|"We view ICG's Lamaque South PEA update positively for its confirmation of increased mine life, higher production rates and lower unit costs."|
|"The endgame for TEN is an asset sale that should rerate the stock."|
|"TV is poised to become a (the) marquee 'pure play' zinc producer."|
|"Commissioning at PVG's Brucejack is on track for early April 2017."|